Topic is suspended
 
Status Suspended
Process TAG

Timeline

Key events during the development of the guidance:

Date Update
01 July 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
01 July 2020 Suspended. Topic is suspended
27 June 2018 In progress. Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance